ECSP024399A - Derivados de benzotiazol - Google Patents

Derivados de benzotiazol

Info

Publication number
ECSP024399A
ECSP024399A EC2002004399A ECSP024399A ECSP024399A EC SP024399 A ECSP024399 A EC SP024399A EC 2002004399 A EC2002004399 A EC 2002004399A EC SP024399 A ECSP024399 A EC SP024399A EC SP024399 A ECSP024399 A EC SP024399A
Authority
EC
Ecuador
Prior art keywords
benzotiazol
derivatives
graph
compounds
treatment
Prior art date
Application number
EC2002004399A
Other languages
English (en)
Inventor
Alexander Flohr
Roger David Norcross
Alexander Alanine
Aubry Kern Miller
Claus Riemer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP024399A publication Critical patent/ECSP024399A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula general (gráfico) y a las sales farmacéuticamente aceptables para el tratamiento de enfermedades relacionadas con el receptor de adenosina.
EC2002004399A 2000-06-21 2002-12-20 Derivados de benzotiazol ECSP024399A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00113219 2000-06-21

Publications (1)

Publication Number Publication Date
ECSP024399A true ECSP024399A (es) 2003-02-06

Family

ID=8169041

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004399A ECSP024399A (es) 2000-06-21 2002-12-20 Derivados de benzotiazol

Country Status (33)

Country Link
US (8) US6521754B2 (es)
EP (2) EP1303272B1 (es)
JP (1) JP3886897B2 (es)
KR (2) KR100571161B1 (es)
CN (1) CN1234358C (es)
AR (1) AR031244A1 (es)
AT (1) ATE385794T1 (es)
AU (2) AU8181701A (es)
BR (1) BR0112395A (es)
CA (1) CA2413086C (es)
CY (1) CY1107401T1 (es)
CZ (1) CZ2003182A3 (es)
DE (1) DE60132777T2 (es)
DK (1) DK1303272T3 (es)
EC (1) ECSP024399A (es)
ES (1) ES2299504T3 (es)
HR (1) HRP20020962A2 (es)
HU (1) HUP0301315A3 (es)
IL (2) IL153278A0 (es)
JO (1) JO2503B1 (es)
MX (1) MXPA02012596A (es)
MY (1) MY138352A (es)
NO (2) NO324635B1 (es)
NZ (1) NZ522928A (es)
PE (1) PE20020104A1 (es)
PL (1) PL207384B1 (es)
PT (1) PT1303272E (es)
RU (1) RU2251419C2 (es)
SI (1) SI1303272T1 (es)
UY (1) UY26782A1 (es)
WO (1) WO2001097786A2 (es)
YU (1) YU96502A (es)
ZA (1) ZA200209730B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3886897B2 (ja) * 2000-06-21 2007-02-28 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
JP4216193B2 (ja) * 2001-11-27 2009-01-28 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
US6624163B2 (en) * 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6713499B2 (en) 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
CN1296368C (zh) * 2001-12-12 2007-01-24 弗·哈夫曼-拉罗切有限公司 用作腺苷受体调节剂的苯并噻吩化合物
HUE039348T2 (hu) 2002-01-28 2018-12-28 Kyowa Hakko Kogyo Kk A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
WO2004002531A1 (ja) * 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 血管の収縮または拡張による疾患治療剤
US6958420B2 (en) * 2002-07-19 2005-10-25 Board Of Trustees Of Michigan State University Synthesis of aminoarylboronic esters and substituted anilines from arenes via catalytic C-H activation/borylation/amination and uses thereof
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
AP2005003319A0 (en) 2002-11-19 2005-06-30 Achillion Pharmaceitucals Inc Substituted aryl thioureas and related compounds; inhibitors of viral replication
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
US7087761B2 (en) * 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
WO2004063177A1 (en) 2003-01-13 2004-07-29 F. Hoffmann-La Roche Ag Benzoxazole derivatives and their use as adenosine receptor ligands
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
PL1636217T3 (pl) * 2003-05-13 2009-02-27 Hoffmann La Roche 1-Imidazobenzotiazole jako ligandy receptora adenozynowego
SI1636223T1 (sl) * 2003-05-19 2008-06-30 Hoffmann La Roche Derivati benzotiazola kot ligandi receptorja adenozina
KR100765565B1 (ko) * 2003-05-21 2007-10-09 에프. 호프만-라 로슈 아게 벤조티아졸 유도체 및 그의 아데노신 에이2에이 수용체에관련된 질병의 치료에서의 용도
ATE396726T1 (de) * 2003-05-30 2008-06-15 Hoffmann La Roche Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten
CA2528785A1 (en) * 2003-06-20 2005-01-06 Matthias Heinrich Nettekoven 2-amidobenzothiazoles as cb1 receptor inverse agonists
AU2004257277B2 (en) * 2003-07-10 2011-03-31 Achillion Pharmaceuticals, Inc. Substituted arylthiourea derivatives useful as inhibitors of viral replication
GEP20094675B (en) * 2003-07-24 2009-05-10 Euro Celtique Sa Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain
NZ545747A (en) 2003-08-06 2010-06-25 Senomyx Inc T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
BRPI0414266A (pt) * 2003-09-19 2006-11-07 Hoffmann La Roche derivados de tiazolopiridina como ligandos receptores da adenosina
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
KR100834179B1 (ko) * 2004-05-24 2008-05-30 에프. 호프만-라 로슈 아게 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드
PT1753760E (pt) * 2004-05-24 2008-02-12 Hoffmann La Roche '' - metoxi - 7 - morfolin - 4 - il - benzotiazol - 2 - il) - amida do ácido 4 - hidroxi - 4 - metil - piperidina - 1 - carboxílico''
JP5202946B2 (ja) * 2004-07-22 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
JP2008506735A (ja) * 2004-07-22 2008-03-06 エフ．ホフマン−ラ　ロシュ　アーゲー 置換されているベンゾチアゾール類
SE0401970D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
US7459563B2 (en) 2004-11-05 2008-12-02 Hoffmann-La Roche Inc. Process for the preparation of isonicotinic acid derivatives
DK1863818T3 (da) 2005-03-23 2010-05-10 Hoffmann La Roche Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
KR101121292B1 (ko) 2005-09-27 2012-04-13 에프. 호프만-라 로슈 아게 Ｍｇｌｕｒ2 길항제로서 옥사다이아졸일 피라졸로-피리미딘
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP1991528A2 (en) * 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
EP2010009B1 (en) 2006-04-21 2017-06-14 Senomyx, Inc. Processes for preparing solid flavorant compositions
US7429589B2 (en) 2006-04-27 2008-09-30 Hoffmann-La Roche Inc. Mono-nitration of aromatic compounds via nitrate salts
CN101448844B (zh) * 2006-05-18 2012-07-25 霍夫曼-拉罗奇有限公司 作为腺苷a2b受体拮抗剂的噻唑并嘧啶/吡啶脲衍生物
GB0612428D0 (en) * 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
WO2008077809A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Process for the manufacture of 7-oxa-bicyclo derivatives
US9284278B2 (en) 2007-02-14 2016-03-15 Basf Se Electroluminescent metal complex
PL2142529T3 (pl) * 2007-04-27 2014-06-30 Purdue Pharma Lp Antagoniści trpv1 i ich zastosowania
EP2182803A4 (en) * 2007-07-23 2010-09-01 Synosia Therapeutics (4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL) -AMIDE 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID FOR TREATING POST-TRAUMATIC STRESS DISORDER
US7913765B2 (en) * 2007-10-19 2011-03-29 Baker Hughes Incorporated Water absorbing or dissolving materials used as an in-flow control device and method of use
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR101064258B1 (ko) 2008-12-29 2011-09-14 한국과학기술연구원 벤조아릴우레이도 화합물, 및 이를 함유하는 퇴행성 뇌질환예방 또는 치료용 조성물
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
WO2010150927A1 (en) * 2009-06-25 2010-12-29 Sk Holdings Co., Ltd. Pharmaceutical composition for prevention and treatment of cancer diseases comprising benzamide derivatives
RU2455293C2 (ru) * 2010-09-15 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) N-(2-бензотиазолил)амид 3-бром-2,4-диоксо-4-(4-метоксифенил)бутановой кислоты, обладающий гипогликемической активностью
RU2448100C1 (ru) * 2010-09-24 2012-04-20 Татьяна Николаевна Иванова Производные 2-аминобензотиазола, обладающие противогипоксической активностью, и способ их использования
US9000154B2 (en) * 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
CN103717594B (zh) 2011-06-22 2016-12-14 普渡制药公司 包含二羟基取代基的trpv1拮抗剂及其用途
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN103772376B (zh) * 2012-10-24 2017-01-11 中国医学科学院医药生物技术研究所 取代的苯并-1,3-杂唑类化合物、其制备方法及用途
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
WO2016109492A1 (en) * 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
WO2017066225A1 (en) * 2015-10-14 2017-04-20 Texas Tech University System Pharmacoperones of the v2 receptor
US11597708B2 (en) 2016-09-16 2023-03-07 Hsf Pharmaceuticals Sa Inhibitors of heat shock factors and uses thereof
AU2018309265B2 (en) * 2017-08-01 2022-06-02 Domain Therapeutics Thiazolopyridine derivatives as adenosine receptor antagonists
CN111542520B (zh) * 2017-09-28 2022-04-15 基石药业（苏州）有限公司 作为a2a受体抑制剂的并环类衍生物
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
DE102019110904B4 (de) * 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
KR102796857B1 (ko) * 2019-10-08 2025-04-15 현대자동차주식회사 냉각장치와 냉각시스템 및 냉각시스템의 제어방법
WO2021119808A1 (en) * 2019-12-16 2021-06-24 The University Of British Columbia Antiviral compounds, compositions and methods of use
WO2021247921A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Benzothiazole compounds and uses thereof
EP4269394A4 (en) * 2021-01-29 2024-07-24 Korea Research Institute of Chemical Technology BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION INCLUDING THEM AS ACTIVE INGREDIENT

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) * 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
GB1318291A (en) * 1970-04-15 1973-05-23 Shell Int Research Carboxamide derivatives and fungicidal compositions containing them
LU63457A1 (es) * 1970-07-06 1971-11-12
JPS5516147B2 (es) * 1971-12-24 1980-04-30
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de) * 1976-12-14 1978-06-15 Boehringer Mannheim Gmbh N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
US4471957A (en) * 1979-12-03 1984-09-18 Baltimore Therapeutic Equipment Company Method and apparatus for rehabilitation of damaged limbs
CA1153867A (en) 1980-05-16 1983-09-20 Michael A. M. Boersma Process for the preparation of crystalline silicates, crystalline silicates so prepared and process for carrying out catalytic reactions
KR930005004B1 (ko) * 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
EP0300688A1 (en) * 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
US5348519A (en) * 1988-02-04 1994-09-20 Loredan Biomedical, Inc. Exercise and diagnostic apparatus and method
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
JPH0667923B2 (ja) 1989-05-11 1994-08-31 東洋紡績株式会社 新規なベンゾチアゾール誘導体
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
ATE103589T1 (de) 1989-11-10 1994-04-15 Agrolinz Agrarchemikalien Verfahren zur herstellung reiner, unsymmetrisch disubstituierter harnstoffe.
US5142910A (en) * 1990-06-27 1992-09-01 Occupational Orthopaedic Systems, Inc. Dynamic physiological function testing apparatus and method
DK0553130T3 (da) * 1990-10-15 1996-02-05 Pfizer Pyrrolidindionderivater
US5275045A (en) * 1991-03-07 1994-01-04 Isotechnologies, Inc. Apparatus and method for use in assessing the lifting capability of a human subject
CN1038586C (zh) * 1991-05-01 1998-06-03 大制药株式会社 吡嗪衍生物的制备方法
EP0604657B1 (en) * 1992-05-21 2000-01-12 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
US5312107A (en) * 1993-05-13 1994-05-17 Kordun, Ltd. Golf club swing training and exercise device
JPH0725858A (ja) * 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
JPH0940646A (ja) * 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd ベンゼン縮合環誘導体又はその塩
FR2753970B1 (fr) 1996-10-01 1998-10-30 Synthelabo Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja) * 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
ID24289A (id) * 1997-11-10 2000-07-13 Bristol Myers Squibb Co Benzotiazol inhibitor-inhibitor protein terosin kinase
WO1999031096A1 (en) * 1997-12-18 1999-06-24 Shaman Pharmaceuticals, Inc. Piperazine derivatives useful as hypoglycemic agents
AU764184B2 (en) * 1998-01-23 2003-08-14 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
AU6280199A (en) 1998-09-30 2000-04-17 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
ES2196917T3 (es) * 1998-12-23 2003-12-16 Lilly Co Eli Amidas heteroaromaticas como inhibidores del factor xa`.
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
EP1237862A1 (en) * 1999-12-17 2002-09-11 Versicor, Inc. Succinate compounds, compositions and methods of use and preparation
JP3886897B2 (ja) * 2000-06-21 2007-02-28 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives

Also Published As

Publication number Publication date
US6835732B2 (en) 2004-12-28
HK1058148A1 (en) 2004-05-07
SI1303272T1 (sl) 2008-06-30
NO20025978D0 (no) 2002-12-12
BR0112395A (pt) 2003-07-08
CY1107401T1 (el) 2012-12-19
KR20050043912A (ko) 2005-05-11
US20080108809A1 (en) 2008-05-08
US20060003986A1 (en) 2006-01-05
AR031244A1 (es) 2003-09-17
HUP0301315A2 (hu) 2003-08-28
ATE385794T1 (de) 2008-03-15
WO2001097786A2 (en) 2001-12-27
US7317007B2 (en) 2008-01-08
JO2503B1 (en) 2009-10-05
US20100075959A1 (en) 2010-03-25
IL153278A0 (en) 2003-07-06
US20030125318A1 (en) 2003-07-03
JP2003535887A (ja) 2003-12-02
EP1303272A2 (en) 2003-04-23
JP3886897B2 (ja) 2007-02-28
YU96502A (sh) 2006-01-16
ES2299504T3 (es) 2008-06-01
NO20025978L (no) 2002-12-12
ZA200209730B (en) 2004-03-01
IL153278A (en) 2012-12-31
HRP20020962A2 (en) 2005-02-28
NZ522928A (en) 2005-05-27
WO2001097786A3 (en) 2002-12-12
HUP0301315A3 (en) 2007-10-29
DK1303272T3 (da) 2008-05-26
US6521754B2 (en) 2003-02-18
AU2001281817B2 (en) 2005-11-24
MXPA02012596A (es) 2003-04-10
PL360697A1 (en) 2004-09-20
US20080125419A1 (en) 2008-05-29
MY138352A (en) 2009-05-29
CN1234358C (zh) 2006-01-04
DE60132777T2 (de) 2009-02-12
NO324635B1 (no) 2007-11-26
CA2413086A1 (en) 2001-12-27
KR20030019446A (ko) 2003-03-06
DE60132777D1 (de) 2008-03-27
PT1303272E (pt) 2008-04-14
CZ2003182A3 (cs) 2003-06-18
NO20073465L (no) 2002-12-12
PL207384B1 (pl) 2010-12-31
AU8181701A (en) 2002-01-02
US20020045615A1 (en) 2002-04-18
KR100526487B1 (ko) 2005-11-08
US20030176695A1 (en) 2003-09-18
US6963000B2 (en) 2005-11-08
CN1437471A (zh) 2003-08-20
US20050026906A1 (en) 2005-02-03
PE20020104A1 (es) 2002-02-16
UY26782A1 (es) 2001-12-28
EP1797878A2 (en) 2007-06-20
CA2413086C (en) 2011-06-28
EP1303272B1 (en) 2008-02-13
KR100571161B1 (ko) 2006-04-17
RU2251419C2 (ru) 2005-05-10
EP1797878A3 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
ECSP024399A (es) Derivados de benzotiazol
UY26872A1 (es) Derivados de la 4- fenil piridina
PA8544901A1 (es) Derivados de oxazol
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
UY26968A1 (es) Agentes terapéuticos
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
ES2161290T3 (es) Derivados de quinazolina.
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
CR6881A (es) Derivados de pirazol
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
PA8507601A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8451801A1 (es) Derivados de la 9-oxima eritromicina
NO20032208D0 (no) Benzodiazepinderivater som GABA A reseptormodulatorer
CR9954A (es) Derivados de pirazina
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
HN2003000272A (es) Formulaciones que comprenden un compuesto de indolinona
HN2003000379A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
AR025046A1 (es) Inhibidores il-5 no esteroidales, procedimientos e intermediarios para su preparacion y composiciones farmaceuticas que comprenden dichos inhibidores